Clinical Trial Update: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update evaluating NALIRIFOX combined with a PD-1 inhibitor and sequential radiotherapy versus NALIRIFOX alone as conversion therapy for…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Onivyde (nanoliposomal irinotecan) (nanoliposomal irinotecan)
• PD-1 inhibitor

Snippet

Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Conditions: Locally Advanced Pancreatic Cancer | Phase 2 | Status: NOT_YET_RECRUITING